5 results match your criteria isograft sdf-1

  • Page 1 of 1

Modulation of the Tumor Microenvironment by CXCR4 Antagonist-Armed Viral Oncotherapy Enhances the Antitumor Efficacy of Dendritic Cell Vaccines against Neuroblastoma in Syngeneic Mice.

Viruses 2018 08 26;10(9). Epub 2018 Aug 26.

Department of Immunology, Roswell Park Comprehensive Cancer Center, Elm and Carlton Streets, Buffalo, NY 14263, USA.

The induction of antitumor immune responses in tumor-bearing hosts depends on efficient uptake and processing of native or modified tumors/self-antigens by dendritic cells (DCs) to activate immune effector cells, as well as the extent of the immunosuppressive network in the tumor microenvironment (TME). Because the C-X-C motif chemokine receptor 4 (CXCR4) for the C-X-C motif chemokine 12 (CXCL12) is involved in signaling interactions between tumor cells and their TME, we used oncolytic virotherapy with a CXCR4 antagonist to investigate whether targeting of the CXCL12/CXCR4 signaling axis in murine neuroblastoma cells (NXS2)-bearing syngeneic mice affects the efficacy of bone marrow (BM)-derived DCs loaded with autologous tumor cells treated with doxorubicin for induction of immunogenic cell death. Here, we show that CXCR4 antagonist expression from an oncolytic vaccinia virus delivered intravenously to mice with neuroblastoma tumors augmented efficacy of the DC vaccines compared to treatments mediated by a soluble CXCR4 antagonist or oncolysis alone. Read More

View Article and Full-Text PDF

CXC Chemokine Receptor Type 4 Antagonism Ameliorated Allograft Fibrosis in Rat Kidney Transplant Model.

Exp Clin Transplant 2017 Aug 5;15(4):448-452. Epub 2017 Jun 5.

From the Department of General Surgery, Tianjin First Central Hospital, Tianjin 300192, China.

Objectives: In this study, we evaluated the effects of CXC chemokine receptor type 4 and stromal cell-derived factor 1 signaling in the progression of chronic allograft nephropathy in a rat model.

Materials And Methods: Experimental rats were divided into 3 groups: Lewis-to-Lewis isograft transplant (group A), Fisher 344 rat-to-Lewis allograft transplant with immunosuppressant cyclosporine (group B), and Fisher 344 rat-to-Lewis allograft transplant treated with cyclosporine and the CXC chemokine receptor type 4 antagonist AMD3100 (1 mg/kg/d) (group C). On day 90 after the operation, renal graft function, proteinuria, and histologic Banff score were measured. Read More

View Article and Full-Text PDF

A kinetic study of SDF-1, VEGF and MCP-1 blood and tissue levels after aortic transplantation in mice.

Acta Histochem 2012 Oct 9;114(6):636-8. Epub 2011 Nov 9.

INSERM U, Institute for Biomedical Research, Rouen University, France.

Vascular rejection is characterized by intimal proliferation and perivascular inflammation. We hypothesize that recipient stem cell therapy could prevent or ameliorate the development of the obliterative lesion. We studied the kinetic expression of three cytokines (SDF-1, MCP-1, VEGF) implicated in mobilization, homing and differentiation of progenitor cells during vascular aggression. Read More

View Article and Full-Text PDF
October 2012

SDF-1 plays a key role in chronic allograft nephropathy in rats.

C Gao J Huan

Transplant Proc 2008 Jun;40(5):1674-8

Burn and Plastic Surgery Department, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Objectives: Our previous study demonstrated that anti-stromal cell derived factor-1 (SDF-1) antibody delayed graft arteriosclerosis in rat abdominal aortic grafts. In this study, we investigated the mechanisms of SDF-1 on chronic allograft nephropathy (CAN), and whether SDF-1 antibody had protective effect on CAN.

Methods: Male Lewis rats that received left renal grafts from male Fisher 344 rats were randomly divided into three groups: group A only received cyclosporine (CsA; 10 mg x kg(-1) x d(-1)) every day; group B received anti-SDF-1 antibody (8 microg x kg(-1) x d(-1)) + CsA (10 mg x kg(-1) x d(-1)); and group C, an isograft control (Fisher 344 to Fisher 344). Read More

View Article and Full-Text PDF

Low molecular weight fucan prevents transplant coronaropathy in rat cardiac allograft model.

Transpl Immunol 2006 Jun 5;16(1):14-9. Epub 2006 Apr 5.

Cardiac and Vascular Surgery Departments, Rouen University Hospital, France.

Introduction: Transplant arteriosclerosis is the main cause of long-term failure after cardiac transplantation. Vascular rejection is thought to be due to intimal proliferation occurring in response to arterial wall immune-mediated injury. A low molecular weight fucan (LMWF) compound, a sulfated polysaccharide, has been demonstrated to increase plasma levels of stromal cell-derived factor 1 (SDF-1) and consequently to mobilize bone marrow-derived vascular progenitor cells (BMVPC). Read More

View Article and Full-Text PDF
  • Page 1 of 1